EQT acquired Qiagen for $10.8B, taking molecular testing private.
EQT Partners is acquiring Qiagen, a molecular testing company, for $10.8 billion in an all-cash deal, marking one of the largest PE-backed acquisitions in diagnostics.
Capital flows, CMO moves, M&A. Eight editions a day, seven tiers, from the chopped neck.
Fresh today 7 new items in the 18:00 utc editionJump to the new edition ↓EQT Partners is acquiring Qiagen, a molecular testing company, for $10.8 billion in an all-cash deal, marking one of the largest PE-backed acquisitions in diagnostics.
Charter Communications released updated financial guidance that assumes its Cox acquisition closed on January 1, 2024, adjusting quarterly results for integration timing.
Oasis Investors initiated a formal proxy campaign against Vail Resorts, seeking four board seats as part of a broader strategy to reshape the mountain resort operator's governance and strategy.
Audax Advisors closed a $10 billion fundraise for direct lending and structured credit investments, positioning the firm to deploy capital into mid-market credit opportunities.
Vishal Garg successfully regained control of Better's board through a shareholder proxy vote, reversing his earlier ouster and signaling a strategic reset at the mortgage technology platform.
Moody's declined to downgrade France's sovereign credit rating despite ongoing political and fiscal challenges, providing a reprieve after weeks of uncertainty about the country's creditworthiness.
Bayview Acquisition Corp. secured its fifth extension to close its initial business combination deal, pushing the deadline further back as negotiations with its target continue.
The branded-identity layer Chiefs of Staff and heritage CMOs route through: your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.